LCAR-AIO T cells
Phase 1Biologic
LCAR-AIO T cells is one of 80 biologic programs targeting Systemic Lupus Erythematosus. It is currently in Phase 1.
3
Indications
3
Total Trials
1
Active Trials
79
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
328 competitors in Systemic Lupus Erythematosus
#DrugCompanyPhaseTrials
1Eptanemab
UCBPhase 3
Medrol
PfizerPhase 3
Rinvoq
AbbViePhase 3
Ocrevus
RochePhase 3
Gazyva
RochePhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Intrarosa
Alnylam PharmaceuticalsPhase 3
Rayos
RRoxane Laboratories
Phase 3
Depo-Provera
Eli LillyPhase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Systemic Lupus Erythematosus1 trial
A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus
Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1·NCT06653556·34 enrolled
Autoimmune Disease1 trial
Multiple Sclerosis (MS)1 trial
An Open Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases
Withdrawn·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1·NCT06869278
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LCAR-AIO T cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- NNanjing Legend Biotech Co.